COVID-19 仍是威胁吗?免疫功能低下人群持续医疗负担的专家意见综述
本文为专家意见综述,汇总近期已发表证据,评估 COVID-19 对免疫功能低下人群的经济与人文影响。文献提示,该人群在 Omicron 前时代住院率、ICU 入住率和机械通气使用率均高,在 Omicron 及以后时期尽管接种疫苗仍保持高位。与无免疫功能低下者相比,该人群焦虑、抑郁和痛苦水平升高,心理健康和健康相关生活质量(HRQoL)受到负面影响,并承受与 COVID-19 相关的可观费用和收入损失,尽管经济负担证据有限。总体而言,COVID-19 增加了多种免疫功能低下患者的医疗资源使用和成本、损害心理健康并降低 HRQoL,凸显持续开展真实世界研究的重要性。
要点
- 免疫功能低下人群对疫苗接种反应欠佳,接种后仍易发生重症 COVID-19。
- 该人群在 Omicron 前时代住院率、ICU 入住率和机械通气使用率高,Omicron 及以后尽管接种疫苗仍保持高位。
- 与无免疫功能低下者相比,该人群焦虑、抑郁和痛苦水平升高,HRQoL 下降。
- 该人群承受与 COVID-19 相关的可观费用和收入损失,但经济负担证据有限。
- 作者认为需持续开展真实世界研究,评估已接种疫苗的免疫功能低下人群的持续负担。
适用人群与场景
- 免疫功能低下个体,包括对疫苗接种反应欠佳、易发生重症 COVID-19 者。
研究设计与关键结果
- 专家意见综述汇总近期已发表证据,显示免疫功能低下人群在 Omicron 前时代住院率、ICU 入住率和机械通气使用率高,在 Omicron 及以后时期尽管接种疫苗仍保持高位。
- 研究提示,与无免疫功能低下状况者相比,该人群焦虑、抑郁和痛苦水平升高,心理健康和 HRQoL 受到负面影响。
- 该人群经历与 COVID-19 相关的可观费用和收入损失,但关于该人群 COVID-19 经济负担的证据有限。
- 总体而言,与未感染 COVID-19 者和一般人群相比,多种免疫功能低下状况患者的医疗资源使用和成本增加、心理健康受损、HRQoL 降低。
证据类型、等级与局限
- 证据类型:专家意见综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需持续开展真实世界研究,评估已接种疫苗但仍面临重症 COVID-19 风险的免疫功能低下人群的持续负担,以确保其需求不会比一般人群更差。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a profound global impact. The emergence of several variants during the pandemic has presented numerous challenges in preventing and managing this disease. The development of vaccines has played a pivotal role in controlling the pandemic, with a significant portion of the global population being vaccinated. This, along with the emergence of less virulent SARS-CoV-2 variants, has led to a reduction in the severity of COVID-19 outcomes for the overall population. Nevertheless, individuals with immunocompromising conditions continue to face challenges given their suboptimal response to vaccination and vulnerability to severe COVID-19. This expert review synthesizes recent published evidence regarding the economic and human impact of COVID-19 on such individuals. The literature suggests that rates of hospitalization, intensive care unit admission, and mechanical ventilation use were high during the pre-Omicron era, and remained high during Omicron and later, despite vaccination for this population. Moreover, studies indicated that these individuals experienced a negative impact on their mental health and health-related quality of life (HRQoL) compared to those without immunocompromising conditions, with elevated levels of anxiety, depression, and distress reported. Further, these individuals with immunocompromising conditions experienced substantial costs associated with COVID-19 and loss of income during the pandemic, though the evidence on the economic burden of COVID-19 in such individuals is limited. Generally, COVID-19 has increased healthcare resource use and costs, impaired mental health, and reduced HRQoL in those with varied immunocompromising conditions compared to both those without COVID-19 and the general population-underscoring the importance of continued real-world studies. Ongoing research is crucial to assess the ongoing burden of COVID-19 in vaccinated individuals with immunocompromising conditions who are still at risk of severe COVID-19 outcomes to ensure their needs are not disproportionately worse than the general population.
参考来源
- Spinner CD, Bell S, Einsele H, et al. Is COVID-19 Still a Threat? An Expert Opinion Review on the Continued Healthcare Burden in Immunocompromised Individuals. Adv Ther. 2024. PMID: 39680311. doi:10.1007/s12325-024-03043-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。